US 11,918,624 B2
Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders
Lajos Baranyi, Gaithersburg, MD (US)
Assigned to Kelsius Laboratories LLC, Baltimore, MD (US)
Filed by Kelsius Laboratories LLC, Baltimore, MD (US)
Filed on Jun. 10, 2020, as Appl. No. 16/898,378.
Prior Publication US 2021/0386821 A1, Dec. 16, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/48 (2006.01); C12N 15/86 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 38/1875 (2013.01); A61K 38/4813 (2013.01); C12N 15/86 (2013.01); A61K 45/06 (2013.01); C12Y 304/17002 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A therapeutic composition comprising an active agent comprising SEQ ID NO: 1.